EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations

Mubashir Aziz, Muhammad Sarfraz, Muhammad Khurrum Ibrahim, Syeda Abida Ejaz iD, Tasneem Zehra, Hanan A Ogaly iD, Mosab Arafat iD, Fatimah A M Al-Zahrani iD, Chen Li

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0292455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Mubashir Aziz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research (DSR), King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer stands as a significant global cause of mortality, predominantly arising from the dysregulation of key enzymes and DNA. One strategic avenue in developing new anticancer agents involves targeting specific proteins within the cancer pathway. Amidst ongoing efforts to enhance the efficacy of anticancer drugs, a range of crucial medications currently interact with DNA at the molecular level, exerting profound biological effects. Our study is driven by the objective to comprehensively explore the potential of two compounds: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (A01) and 5-fluoro-1H-pyrimidine-2,4-dione (A02). These compounds have demonstrated marked efficacy against breast and cervical cancer cell lines, positioning them as promising anticancer candidates. In our investigation, A01 has emerged as a particularly potent candidate, with its potential bolstered by corroborative evidence from lactate dehydrogenase release and caspase-3 activity assays. On the other hand, A02 has exhibited remarkable anticancer potential. To further elucidate their molecular mechanisms and interactions, we employed computational techniques, including molecular docking and molecular dynamics simulations. Notably, our computational analyses suggest that the A01-DNA complex predominantly interacts via the minor groove, imparting significant insights into its mechanism of action. While earlier studies have also highlighted the anticancer activity of A01, our research contributes by providing a deeper understanding of its binding mechanisms through computational investigations. This knowledge holds potential for designing more effective drugs that target cancer-associated proteins. These findings lay a robust groundwork for future inquiries and propose that derivatives of A01 could be synthesized as potent bioactive agents for cancer treatment. By elucidating the distinctive aspects of our study’s outcomes, we address the concern of distinguishing our findings from those of prior research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansCaspase 3Molecular Docking SimulationL-Lactate DehydrogenasePyrimidinesDNAStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular Structure

Substanzen

Caspase 3L-Lactate DehydrogenaseAntineoplastic AgentsPyrimidinesDNA

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
  • College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates.
  • Baqai Medical University, Karachi, Pakistan.
  • Department of Basic Science & Humanities, Dawood University of Engineering & Technology, Karachi, Pakistan.
  • Chemistry Department, College of Science, King Khalid University, Abha, Saudi Arabia.
  • Department of Biology, Chemistry, Pharmacy, Free University of Berlin, Berlin, Germany.

ORCID-Profile: Syeda Abida Ejaz, Hanan A Ogaly, Mosab Arafat, Fatimah A M Al-Zahrani

Förderung

  • Deanship of Scientific Research (DSR), King Khalid University

Zitieren

APA

Aziz, M., Sarfraz, M., Khurrum Ibrahim, M., Ejaz, S. A., Zehra, T., Ogaly, H. A., Arafat, M., Al-Zahrani, F. A. M., & Li, C. (2023). Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations. PLOS ONE. https://doi.org/10.1371/journal.pone.0292455

Vancouver

Aziz M, Sarfraz M, Khurrum Ibrahim M, Ejaz SA, Zehra T, Ogaly HA, et al. Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations. PLOS ONE. 2023. doi:10.1371/journal.pone.0292455

BibTeX
@article{Aziz2023,
  author = {Aziz, Mubashir and Sarfraz, Muhammad and Khurrum Ibrahim, Muhammad and Ejaz, Syeda Abida and Zehra, Tasneem and Ogaly, Hanan A and Arafat, Mosab and Al-Zahrani, Fatimah A M and Li, Chen},
  title = {Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0292455}
}
Kostenlos starten →